Compare SRTA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | GYRE |
|---|---|---|
| Founded | 2014 | 2002 |
| Country | United States | United States |
| Employees | 601 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 606.4M |
| IPO Year | N/A | 2004 |
| Metric | SRTA | GYRE |
|---|---|---|
| Price | $5.11 | $6.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $7.81 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.3M | 107.1K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $275,000.00 |
| Revenue This Year | $39.27 | $19.88 |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.85 | $5.44 |
| 52 Week High | $6.50 | $9.42 |
| Indicator | SRTA | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 44.86 |
| Support Level | $4.76 | $5.59 |
| Resistance Level | $5.16 | $8.28 |
| Average True Range (ATR) | 0.22 | 0.35 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 17.86 | 10.95 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.